Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 4th May 2018
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Liverpool antibiotic research receives funding boost
SPR206 may be safer and just as effective as colistin.
Funding will support the development of SPR206

A grant of £250k has been awarded to the University of Liverpool to develop antibiotics for multi-drug resistant bacteria.

The money, awarded by biopharmaceutical company Spero Therapeutics, will be used by the University’s Centre for Antimicrobial Pharmacodynamics (CAP) for the development of SPR206.

Initial research suggests this new antibiotic may be safer and just as effective as colistin. In the NHS, colistin is only used as a last resort treatment of multi-drug resistant bacteria because it is highly toxic.

The research will be conducted by Dr Shampa Das and Professor William Hope.

Professor Hope said: “This funding will help support further work of the CAP, where the principal task is to identify regimens to take into first-in-patient clinical studies.”

The discovery of SPR206 and its development is being supported by the National Institute for Allergy and Infectious Diseases, National Institutes of Health. 

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.